Seres Therapeutics Stock Performance
| MCRB Stock | USD 14.07 0.01 0.07% |
Seres Therapeutics holds a performance score of 13 on a scale of zero to a hundred. The entity has a beta of 3.22, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Seres Therapeutics will likely underperform. Use Seres Therapeutics expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to analyze future returns on Seres Therapeutics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Seres Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, Seres Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.07) | Five Day Return 14.11 | Year To Date Return (16.60) | Ten Year Return (98.34) | All Time Return (98.63) |
Last Split Factor 1:20 | Last Split Date 2025-04-22 |
1 | Disposition of 2656 shares by Desrosier Thomas of Seres Therapeutics subject to Rule 16b-3 | 05/02/2025 |
2 | Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | 05/07/2025 |
3 | MCRB Seres Therapeutics Price Target Raised by Chardan Capital MCRB Stock News | 05/08/2025 |
4 | Disposition of 140 shares by Matthew Henn of Seres Therapeutics subject to Rule 16b-3 | 05/15/2025 |
5 | Wall Street Analysts Believe Seres Therapeutics Could Rally 713.09 percent Heres is How to Trade | 05/16/2025 |
6 | Disposition of tradable shares by Matthew Henn of Seres Therapeutics subject to Rule 16b-3 | 05/19/2025 |
7 | Seres Therapeutics Upgraded to Buy What Does It Mean for the Stock | 05/23/2025 |
8 | Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting | 05/27/2025 |
9 | Disposition of 12726 shares by Shaff Eric D. of Seres Therapeutics at 0.8105 subject to Rule 16b-3 | 06/03/2025 |
10 | 1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 2025-2030 | 06/05/2025 |
11 | Acquisition by Fraser Claire of 6452 shares of Seres Therapeutics at 10.71 subject to Rule 16b-3 | 07/01/2025 |
| Begin Period Cash Flow | 136.2 M | |
| Total Cashflows From Investing Activities | 142.3 M |
Seres Therapeutics Relative Risk vs. Return Landscape
If you would invest 748.00 in Seres Therapeutics on April 21, 2025 and sell it today you would earn a total of 659.00 from holding Seres Therapeutics or generate 88.1% return on investment over 90 days. Seres Therapeutics is currently generating 1.2519% in daily expected returns and assumes 7.1867% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than Seres, and 75% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Seres Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seres Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Seres Therapeutics, and traders can use it to determine the average amount a Seres Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1742
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MCRB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.19 actual daily | 64 64% of assets are less volatile |
Expected Return
| 1.25 actual daily | 25 75% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Seres Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Seres Therapeutics by adding it to a well-diversified portfolio.
Seres Therapeutics Fundamentals Growth
Seres Stock prices reflect investors' perceptions of the future prospects and financial health of Seres Therapeutics, and Seres Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Seres Stock performance.
| Return On Equity | -15.56 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 158.8 M | ||||
| Shares Outstanding | 8.73 M | ||||
| Price To Earning | (4.04) X | ||||
| Price To Book | 2.54 X | ||||
| Price To Sales | 390.27 X | ||||
| Gross Profit | (18.05 M) | ||||
| EBITDA | (121.31 M) | ||||
| Net Income | 136 K | ||||
| Cash And Equivalents | 195.8 M | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 91.64 M | ||||
| Debt To Equity | 3.35 % | ||||
| Current Ratio | 2.35 X | ||||
| Book Value Per Share | 5.78 X | ||||
| Cash Flow From Operations | (148.61 M) | ||||
| Earnings Per Share | (7.95) X | ||||
| Market Capitalization | 122.87 M | ||||
| Total Asset | 139.81 M | ||||
| Retained Earnings | (978.1 M) | ||||
| Working Capital | (2.55 M) | ||||
| Current Asset | 207.61 M | ||||
| Current Liabilities | 10.92 M | ||||
About Seres Therapeutics Performance
By analyzing Seres Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Seres Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Seres Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Seres Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 13.8 K | 14.5 K | |
| Return On Capital Employed | (1.23) | (1.29) | |
| Return On Equity | 0.01 | 0.01 |
Things to note about Seres Therapeutics performance evaluation
Checking the ongoing alerts about Seres Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Seres Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Seres Therapeutics is way too risky over 90 days horizon | |
| Seres Therapeutics appears to be risky and price may revert if volatility continues | |
| Seres Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Seres Therapeutics currently holds about 195.8 M in cash with (148.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.58. | |
| Seres Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 13.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Seres Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Seres Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Seres Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Seres Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Seres Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Seres Therapeutics' stock. These opinions can provide insight into Seres Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |